Saphnelo (anifrolumab-fnia) - AstraZeneca
Case Report: Anifrolumab for Refractory Cutaneous Lupus Erythematosus: Relapse After Treatment Interruption and Response to Rechallenge. (PubMed, Int J Rheum Dis) - Sep 15, 2026 - No abstract available 
Journal • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus
http://www.ncbi.nlm.nih.gov/pubmed/42735674
 
Farina Tariq; Muhammad Zaheer; Seth Stidham; Yuanzun Peng
 
Sep 15, 2026
 
Prev Next